Cristina
Bueno-Díaz
*a,
Marit
Zuurveld
a,
Verónica
Ayechu-Muruzabal
a,
Sandra G. P. J.
Korsten
ae,
Laura
Martín-Pedraza
b,
Jorge
Parrón-Ballesteros
c,
Frank
Redegeld
a,
Johan
Garssen
ad,
Mayte
Villalba
c and
Linette E. M.
Willemsen
*a
aDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands. E-mail: l.e.m.willemsen@uu.nl
bHospital Ramón y Cajal, Madrid, Spain
cDepartment of Biochemistry and Molecular Biology, Complutense University of Madrid, Madrid, Spain
dDanone Nutricia Research B.V., Utrecht, The Netherlands
eTiofarma B.V., Oud-Beijerland, The Netherlands
First published on 17th May 2024
Mustard seeds belong to the food category of mandatory labelling due to the severe reactions they can trigger in allergic patients. However, the mechanisms underlying allergic sensitization to mustard seeds are poorly understood. The aim of this work is to study type 2 immune activation induced by the mustard seed major allergen Sin a1 via the intestinal mucosa, employing an in vitro model mimicking allergen exposure via the intestinal epithelial cells (IECs). Sin a1 was isolated from the total protein extract and exposed to IEC, monocyte derived dendritic cells (DCs) or IEC/DC co-cultures. A system of consecutive co-cultures was employed to study the generic capacity of Sin a1 to induce type 2 activation leading to sensitization: IEC/DC, DC/T-cell, T/B-cell and stem cell derived mast cells (MCs) derived from healthy donors. Immune profiles were determined by ELISA and flow cytometry. Sin a1 activated IEC and induced type-2 cytokine secretion in IEC/DC co-culture or DC alone (IL-15, IL-25 and TSLP), and primed DC induced type 2 T-cell skewing. IgG secretion in the T-cell/B-cell phase was enhanced in the presence of Sin a1 in the first stages of the co-culture. Anti-IgE did not induce degranulation but promoted IL-13 and IL-4 release by MC primed with the supernatant from B-cells co-cultured with Sin a1-IEC/DC or -DC primed T-cells. Sin a1 enhanced the release of type-2 inflammatory mediators by epithelial and dendritic cells; the latter instructed generic type-2 responses in T-cells that resulted in B-cell activation, and finally MC activation upon anti-IgE exposure. This indicates that via activation of IEC and/or DC, mustard seed allergen Sin a1 is capable of driving type 2 immunity which may lead to allergic sensitization.
Intestinal epithelial barrier homeostasis is highly regulated by its interplay with both the microbiota and the mucosal immune system, and also with external components like those that come from food.3 The disruption of this homeostasis can lead to the loss of oral tolerance and the development of food allergies.4 The intrinsic properties of major food allergens may contribute to epithelial activation and drive the development of type 2 dendritic cell (DC) activation, the first steps in the immune cascade leading towards allergic sensitization.5,6
Among allergenic sources, plant-derived foods comprise an important percentage of the reported type-I hypersensitivity reactions against food products.7,8 Most allergenic proteins are resistant to digestion allowing crucial epitopes to be recognized by the mucosal immune system.9
Many frequently consumed foods, such as pizza and tomato sauce, contain mustard seeds as a taste enhancer. Thus, despite its relatively low sensitization prevalence,10,11 its ubiquity in meals and the severity of reactions associated with its accidental consumption make mustard one of the foods that must be included on food labels.12 At a clinical level, most patients allergic to mustard seeds are sensitized to Sin a1,13 belonging to the 2S albumin family, along with also major allergens from peanut (Ara h 2 and Ara h 6), hazelnut (Cor a 14) or cashew (Ana o 3). These proteins are characterized by their structural resistance to thermal and enzymatic treatments,14,15 also by their interaction with lipidic components and, consequently, with cell membranes.16,17 Previous studies reported the ability of different 2S albumins to cross intestinal cell monolayers, without affecting permeability, while activating these epithelial cells to produce immune mediators.18,19 However, it is unknown if this would provoke epithelial activation for Sin a1, then contributing to allergic sensitization and food allergy development.20 Therefore, in the present work, human intestinal epithelial cells (IECs) were used to study the sensitizing capacity of Sin a1 through the intestinal mucosa. Moreover, a sequential co-culture system developed by our group21 was employed to further determine if Sin a1 exposure could drive the type 2 phenotype in innate and adaptive immune cells.
Fractions containing proteins under 30 kDa followed were pooled together, lyophilized and resuspended in 3 mM ammonium pyrophosphate for its application in a SP-Sephadex C-25 (Sigma-Aldrich) ion exchange column, in a 3 to 50 mM sodium pyrophosphate gradient. Protein purification was traced by SDS-PAGE and western blotting using a polyclonal antibody against Sin a1 (ESI Fig. 1†). Fractions containing Sin a1 were pooled together for buffer exchange into ammonium bicarbonate, 50 mM, by centrifugation in 10 kDa size pore Amicon 15 mL tubes (Merck Millipore). After all the purification process, a total of 1 mg of Sin a1 was purified from 20 mg of the total mustard seed extract (5% of total protein).
LPS was removed with Pierce© High-Capacity Endotoxin Removal Spin Columns (Thermo Fisher Scientific). Final endotoxin levels were determined with Endosafe®-PTS Endotoxin test (Charles River Microbial Solutions). Since endotoxin activity was below the limit of detection (0.1 EU mL−1), samples were considered “LPS-free”.
Caco-2 cells were seeded in 12-well transwell inserts. Once the cells were differentiated (day 21 after confluence, TEER ≥ 500 Ω cm2), Sin a1 was added (0–25 μg mL−1) in the apical compartment (Fig. 1B), after 24 h basolateral supernatants were collected for cytokine analysis by ELISA. Barrier integrity was studied by measuring TEER and FITC-dextran (3–5 kDa; Sigma-Aldrich) permeability one hour after apical application.
For the IEC/DC co-culture, HT-29 cells were seeded in 6-wells of a 12-well transwell insert plate (Costar) until they reached confluence. Then, 5 × 105 DCs were added to each well in the basolateral compartment; so two conditions were analysed: IEC-DCs or DCs in the absence of epithelial cells. Apically, 25 μg mL−1 Sin a1 was added to the cultures for 48 h. DC control conditions were placed in a separate 12-well plate, using 100 ng mL−1 LPS (type 1 DC profile) or DC2-mix (50 ng mL−1 TNFα, 25 ng mL−1 IL-1β, 10 ng mL−1 IL-6 and 1 μg mL−1 PGE2; type 2 DC profile) as previously described.24
Next step was the DC/T-cell co-culture (10:
1 ratio, T
:
DC) for 96 h in the presence of 5 ng mL−1 IL-2 (Prospec) and 150 ng mL−1 anti-CD3 (BD Biosciences), washing the DCs prior to incubation with T cells, to avoid the presence of Sin a1 in the supernatant. Appropriate T-cell control conditions included: anti-CD3 + IL-2 stimulated, and non-stimulated cells cultured in the absence of DC.
Next, T-cells were co-cultured with B-cells (1:
1 ratio) in the presence of 5 μg mL−1 anti-IgM (Sigma-Aldrich), employing appropriate B-cell controls as described previously.21 Finally, B-cells were collected for flow cytometry analysis, while supernatants were employed for cytokine determination and MC degranulation and activation assays. For this purpose, MCs were incubated overnight with B cell supernatants. Afterwards, cell medium was replaced and anti-IgE was added, measuring MC degranulation after 1 hour incubation (β-hexosaminidase release), and type 2 cytokine (IL-4 and IL-13) secretion 18 hours after exposure to anti-IgE.
For DC analyses, CD11c + HLA-DR + population was gated from the life cells. Subsequently, the expression of activation markers CD80, CD86, and OX40L was assessed and reported as percentages in DCs (see ESI Fig. 6† for gating strategy including FMO controls).
For T cells, CD4+ population was gated within the life cell population. Then, the expression of CRTH2, CXCR3 and intracellular IL-13 markers was assessed in the CD4+ population and expressed as median MFI or percentage of cells (ESI Fig. 4 and 7† for gating strategy including FMO controls). Finally, B cells were selected over T cells according to CD19 expression. For those CD19+ cells, CD25 and CD27 markers were measured and expressed as percentage of cells.
First, HT-29 cells were grown confluent in 48-well flat bottom plates and exposed to increasing concentrations of purified Sin a1 for 24 h (Fig. 2B). In ESI Fig. 1† the purification of Sin a1 from the YMSE is shown (ESI Fig. 1†). Sin a1 increased CCL20 and IL-33 concentrations in a dose-dependent manner, while CCL22 and IL-8 remained unaffected, and TSLP was not detected (Fig. 2C). Moreover, Sin a1 did not affect cell viability and neither YMSE nor LPS was capable of inducing epithelial activation into type-2 profile like Sin a1. The 62.5 μg ml−1 dose of YMSE induced IL-8 secretion by HT-29 cells (ESI Fig. 2A–C†).
To study the effects of Sin a1 on epithelial barrier properties, Caco-2 cells were cultured in 12-well transwell inserts, and 21 days after reaching confluence, exposed to different concentrations of Sin a1 for 24 h (ESI Fig. 3A†). The presence of the allergen did not affect cell viability according to the WST-1 test, nor TEER or 3–5 kDa FITC dextran permeability (ESI Fig. 3B and C†). The highest dose of Sin a1 enhanced CCL20 (p < 0.01) release by IEC, while IL-33 levels increased (p < 0.05) using 5 μg mL−1 Sin a1 (ESI Fig. 3D†). No significant changes were observed in CCL22, and neither TSLP nor IL-8 were detectable.
These results suggest an ability of Sin a1 to interact and activate epithelial cells to initiate a pro-allergenic immune response. Since in HT-29 Sin a1 dose-dependently increased both IL-33 and CCL20, these cells were chosen to further study the effects of epithelial activation by Sin a1 on DC maturation and downstream type 2 polarization using a dose of 25 μg mL−1.
The first step of this system consisted of two initial conditions established in a transwell plate: HT-29 co-culture with DC (IEC-DC) or DC alone. In both cases, cells were exposed to a single dose of Sin a1 in the apical compartment (Fig. 3A). After 48 h, analysis of target cytokines from the basolateral compartment revealed immune activation having both a type-2 and type-1 phenotype (Fig. 3B), either in the presence or absence of HT-29 in the apical compartment. Sin a1 increased IL-25 (p < 0.05; p < 0.01), CCL20 (p < 0.01; p < 0.005), and IL-15 levels (p < 0.005; p < 0.001). The presence of IEC reduced CD86 expression in DC in the presence or absence of Sin a1, while CD80 tended to increase (Fig. 3C). Sin a1 did not affect OX40L, CD86 nor CD80 expression of DC compared to medium controls in the presence or absence of IEC. Maturation controls using LPS (DC1) or cytokine mix (DC2) showed a tendency towards the increase of OX40L and CD80 and increased CCL20 and/or CCL22 secretion of matured DC compared to medium controls.
Next step in the sensitization phase is the interaction of DC with T-cells. Therefore, the primed DCs were cultured in the presence of allogenic naïve T-cells for four days (Fig. 4A) and cytokine profiles and T-cell phenotypes were determined. Cytokine analysis revealed a significant increment in IL-4 in both IEC-DC/T-cells (p < 0.001) and DC/T-cells (p < 0.01) when either IEC-DC or DC had been exposed to Sin a1 in the previous step (Fig. 4B). IL-10 followed a similar tendency. IL-17 concentrations remained unaffected and showed a declining pattern in the Sin a1 DC/T-cell culture. Flow cytometry showed a significant increment in intracellular IL-13 expression (p < 0.05) in those T-cells from the IEC-DC/T-cell when IEC had been exposed to Sin a1. Furthermore, DCs that were directly exposed to Sin a1 tended to increase the expression of CRTH2 (Th2 marker) on T cells, while the expression of CXCR3 (Th1 marker) and the frequency of CXCR3 expressing T-cells was reduced (Fig. 4C and ESI Fig. 4B†). Moreover, the ratio MFI CRTH2/MFI CXCR3 significantly increased in this condition, and also in the DC2/T-cell control, indicating a shift in the balance towards the Th2 profile (Fig. 4C). Control DC/T-cell cultures of T-cells exposed to matured DC1 (LPS) or DC2 showed increased TNF secretion, and in DC2/T-cell cultures also IL-13 secretion increased, while IL-4 showed a similar inclining pattern.
![]() | ||
Fig. 5 Co-culture of Sin a1 exposed IEC-DC or DC-primed T-cells with naïve B-cells. (A) T-cells primed with DCs that were previously exposed to Sin a1 exposed IEC or DC directly exposed to Sin a1 were co-cultured with autologous naïve B-cells for four up to 18 days (n = 3 independent donors). T/B-cell supernatants were collected to measure IgE and IgG antibody levels (B), while the B cell phenotype was determined by flow cytometry (C). Controls are B-cells alone, medium-exposed (B-cell), anti-IgM exposed (aIgM), or anti-IgM + antiCD40 + IL-4 (IgE mix). Data were analysed by one-way ANOVA, or by paired t-test for CTRL vs. DC2, mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001). IL-4 and IL-13 data are shown in ESI Fig. 5.† |
Finally, supernatants obtained from both IEC-DC-T/B-cell and DC-T/B-cell co-cultures were exposed over night to primary human MC to determine effector cell activation mediated by antibodies produced by B-cells in the previous step (Fig. 6A). In the conditions with the T/B-cell supernatants of the Sin a1 exposed IEC/DC or DC primed T-cells anti-IgE induced MC degranulation tended to increase when using the day 4 supernatants, while this effect was lost using the day 18 supernatants (Fig. 6B). However, both the day 4 and day 18 supernatant from the Sin a1-IEC-DC-T/B-cell co-culture induced IL-13 secretion by exposed MC (p < 0.05), while this was also the case for the Sin a1-DC-T/B-cell supernatant of day 18 (Fig. 6C). IL-4 was significantly increased in the supernatants of MC exposed to 18 days Sin a1-DC-T/B-cell supernatant (ESI Fig. 5B†). These results reveal Sin a1 exposed IEC/DC or DC to drive an immune cascade, resulting in MC activation as indicated by type 2 cytokine secretion. 18 days T/B-cell supernatant of DC2 primed T-cells also facilitated anti-IgE provoked MC degranulation, while day 4 supernatant enhanced IL-13 secretion by MC and a similar pattern was observed with the day 18 supernatant (Fig. 6A–C). The background in MC degranulation upon anti-IgE exposure was negligible, while IgE exposed MC showed a percentage of degranulation of more than 60%, while tending to increase IL-13 secretion (n = 1, data not shown).
![]() | ||
Fig. 6 Mast cell degranulation and IL-13 release. (A) Mast cells were cultured overnight in the supernatant from T-cell/B-cell co-culture (n = 3 independent T/B cell donors) of T-cells that were previously exposed to primed DC from Sin a1 exposed IECs or DCs directly exposed to Sin a1. Mast cells were washed and incubated with anti-IgE. Mast cell degranulation and activation were determined by β-hexosaminidase release (B), and IL-13 levels (C), respectively. Data were analysed by one-way ANOVA, or by paired t-test for CTRL vs. DC2, mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. IL-4 data are shown in ESI Fig. 5.† |
Allergen interaction with IEC has been addressed in the past, and mainly focused on the transport of proteins across the epithelial barrier.19,26,27 However, little information can be found regarding epithelial activation and further type-2 immune polarization.28,29 Murine models of peanut and egg allergy are already available,30,31 and a similar model could be developed for Sin a1; however, results may be affected by mouse strains and the sensitization route.32,33 Moreover, the actual politics towards animal experimentation makes necessary the development of suitable in vitro tools that, if not replace murine models, reduce their use.34,35 In the present study, a novel developed sequential human in vitro co-culture model was used to study sensitizing allergenicity.21 Similar to the reported results for egg allergen ovalbumin, Sin a1 was capable of independently activating IECs and DCs, first step in allergy development. Sin a1 was washed after incubation with IEC and/or DC. Both IECs and DCs were however activated by the previous exposure to Sin a1 to promote secretion of type 2 mediators. Moreover, this activation leads to generic type-2 T-cells that prime B-cells to produce more IgG. Even though no increase in IgE was observed, the mast cell supernatant did facilitate anti-IgE-induced MC activation, indicating a functional IgE response could be triggered by upstream Sin a1 exposure of IEC/DC or DC. These findings show the intrinsic capacity of Sin a1 to promote type 2 immunity, either via IEC (structural cells) or directly via DC (innate immune cells) in a similar manner.
Direct exposure of IEC to Sin a1 induced epithelial activation and the release of CCL20 and IL-33, key mediators in starting a type-2 immune response. These results were in line with those reported for Pru p 3,28 a major allergen from peach; however, cytokine profiles were determined at the mRNA level. Only isolated Sin a1 and not YMSE, containing the same amount of target allergen, induced epithelial activation into a type-2 profile. YMSE contains not only allergenic proteins but also other components, such as polyphenols and pigments, that may interfere in the epithelial response to allergens.36 Even though within its matrix, Sin a1 did not activate IEC, in vivo Sin a1 may be released from the protective food matrix as it may escape from digestion,37 allowing its allergenic properties.38,39
HT-29 and Caco-2 have been generally used to test allergen transport and epithelial activation.40 In the current study, we used both cell lines to study the effects of Sin a1. As Caco-2 cells are known to polarize in culture and the gold standard in performing intestinal barrier studies, we studied effects of Sin a1 on TEER and functional permeability (4 kDa FITC dextran) in these cells. Sin a1 was not consistently found to affect epithelial barrier properties (ESI Fig. 3†). However, other 2S albumins have been reported to cross epithelial lining via transepithelial transport,18,19 hence also without affecting tight junction permeability. Beyond studying barrier effects, the purpose of our studies was to study the capability of Sin a1 to activate epithelial cells. For this purpose, we used HT29 and Caco-2 cells. In both cell lines, Sin a1 was able to enhance CCL20 and IL33 release; albeit these effects were most strong in HT-29 which showed greater levels in the release of these type 2 mediators. Therefore, the HT-29 cells were used for the follow up studies, to study the effect of epithelial activation on DC phenotype and function and consequent type 2 immune development. This novel mucosal immune model represents a first step in studying the possible contribution of IEC in sensitizing allergenicity of food allergens. In this model, cell lines were used, which are of carcinogenic origin, and therefore may not be representative of physiological conditions regarding type-2 response development due to their inflammatory background.41,42 Future studies may therefore make use of primary human IEC cultures to further validate the use of these generally used model cell lines to study sensitizing allergenicity of proteins to predict risk on food allergy.43 Nonetheless, primary intestinal epithelial cell cultures have constraints in terms of availability, since obtaining these cultures usually requires special permits for biopsies from donors. Another alternative is intestinal organoids; however, these are of foetal origin, which may not be representative in the case of mustard seed allergy since this is not an early-life allergy. Furthermore, organoids require complex high-priced treatment to expose their apical side and need 2D culture conditions.44 For these reasons, the epithelial models employed in the present study may represent an easy-to-use and economy-wise first approximation in identifying type 2 driving capacity of food proteins.
Regarding the immune response driven by Sin a1, the allergen induced the release of type-2 mediators by DC, such as CCL20, IL-15 and IL-25, independent of IEC and a similar pattern was observed for IL-8 and TSLP.45–47 Moreover, a similar response was observed upon Sin a1 exposure via IEC in the IEC/DC coculture; however, here the contribution of IECs in DC priming remains unclear. Nevertheless, previous data from our group demonstrated that allergen pre-exposed IECs were capable of priming DCs, inducing a shift in the immune response towards the type-2 profile.48 Furthermore, the outcome of the T-cell and mast cell response did differ in some aspects, indicating that Sin a1 exposure to IEC/DC may have modified the function of the primed DCs when compared to direct exposure of DCs. Although IL-33, TSLP and IL-25 release is canonically attributed to IECs, recent studies have described that DCs can produce these cytokines in a type-2 environment.49 On the other hand, control DCs exposed to LPS or DC2 cytokine mix showed increased secretion of CCL20 and/or CCL22. Sin a1 therefore differentially affected DC properties compared to these controls. In contrast to studies using OVA,21 Sin a1 did enhance DC maturation markers. Beyond the difference in dose, and the OVA source containing some LPS contamination, also differences in allergen structural characteristics between Sin a1 and OVA may explain these discrepancies.9,50 Moreover, Sin a1-primed IEC-DCs and DCs were functionally affected since they were capable of inducing IL-4 release by T-cells. Furthermore, intracellular IL-13 expression in T-cells was significantly enhanced after their co-culture with Sin a1-IEC-DC, while the Sin a1-DC/T-cell condition decreased the frequency of Th1 (CXCR3) cells and increased Th2 (CRTH2) over Th1 balance. These findings reinforced the idea of Sin a1 induced epithelial activation, shifting the immune balance towards the type-2 profile.51 However, also in the absence of IECs, Sin a1 was able to affect DC properties leading to type 2 T-cell characteristics, indicating that Sin a1 activation of IECs is not an absolute requirement to enable mucosal sensitization to Sin a1.
When addressing the interaction of T-cells with B-cells, no significant changes were observed in the expression of activation markers, nor in the IgE levels. However, the DC2-T/B-cell controls nor B-cell controls that were found to enhance B-cell maturation (CD27 expression) and/or activation (CD25 expression) also did not show enhanced IgE or IgG secretion. In contrast, in previous studies, OVA exposed IEC-DC-T/B-cells were found to secrete IgE after 18 days.21 Sin a1 exposed IEC-DC-T/B-cells or Sin a1 DC-T/B-cells did show increased total IgG in the supernatants, already after day 4 of co-culture. Class-switching from IgM to IgE is a sequential process, obtaining IgG as intermediate necessary for affinity maturation of the antibody.52 However, after 18 days of co-culture, still only increase in IgG was detected.
However, even though Sin a1 exposure to IECs/DCs or DCs did not result in the instruction of B-cells to produce humoral factors facilitating full mast cell degranulation; similar to hen's egg allergen ovalbumin,21 mast cells were activated since IL-13 and IL-4 was released by the mast cells. Indeed IgE receptor crosslinking can lead to mast cell degranulation and/or cytokine secretion. It is known that anti-IgE dependent MC activation could be provoked as shown by IL-13 release.53 This may indicate that IgE present in the Sin a1 condition is functionally different from that in the control condition, leading to higher sensitivity for anti-IgE crosslinking and thus mast cell activation.54 Hence, we hypothesize that in the current set up the Sin a1 signal on IECs/DCs or DCs was not strong enough to fully give rise to increased IgE levels. Therefore, anti-IgE may not be capable of activating the mast cell degranulation pathway, but could induce type 2 cytokine (IL-4 and IL-13) secretion by mast cells which could further drive the pathway of allergic sensitization. Alternatively, other humoral factors present in the B-cell supernatant could influence anti-IgE mediated mast cell degranulation and type 2 activation as well. IgE mediated mast cell degranulation can be affected by regulatory mediators such as IL-10 and TGFβ, or other immunoglobulins such as inhibitory IgG4.55 In addition, future studies could aim to quantify the amount of IgE bound to the mast cells, which may differ between conditions, as indication of sensitization. Thus by including the primary human mast cells in this sequential model to study the sensitizing capacities of Sin a1, it was aimed to gain insight into the full phenotype of B-cell activation and its capacity to provoke allergic symptoms.
In this model, however, generic and not allergen specific mast cell degranulation was studied. Generation of allergen specific IgE would require both T- and B-cells capable of recognizing Sin a1 via either the T-cell or B-cell receptor. Chances of having present naïve T-cells and B-cells that can recognize Sin a1 within a healthy donor population is very small. Hence, in the current assay it was not aimed to study allergen specific responses, but the generic capacity of Sin a1 to drive type 2 responses via activating IECs and/or DCs. Studying allergen specific responses would be possible when making use of PBMC derived from allergic patients which already have more T and B cells in their repertoire to recognize the allergen.56
On the other hand, beyond IgE there are also other factors, such as IL-4 secretion by other immune cells, that can cause mast cell activation.57 IL-4 was detected in supernatants from T/B-cell cultures at day 18, but these were not affected by the Sin a1 conditions, and at day 4, IL-4 was not detected. Still, in MC exposed to these B-cell supernatants, IL-13 release was observed under Sin a1 exposed conditions. However, these were not associated with the presence of IL-4 in the B-cell supernatants, thus IL-4 was not responsible for the mast cell activation upon exposure to the T/B-cell supernatants (ESI Fig. 5†). Alternatively suboptimal activation of mast cells through FcεRI has been described as another possible explanation to cause mast cell activation without degranulation,58,59 in accordance with our results.
The supernatants from DC2-T/B-cell controls were found to facilitate IL-13 production (day 4 and 18) and degranulation (day 18) of MCs upon anti-IgE exposure also implying sensitization of MCs. This suggests that exposure to Sin a1 via IEC-DC or DCs induced sequential immune polarization and immunoglobulin class-switching, resulting in MC priming.
In conclusion, mustard seed allergen Sin a1 was shown to enhance type 2 activation of IECs as well as DCs, leading to type 2 skewing of the T-cells and humoral response in B-cells, facilitating MC activation resulting in IL-4 and IL-13 release. The present model may be further explored to identify the intrinsic activity of food proteins to induce type 2 activation which could lead to sensitization for these proteins. Furthermore, it could help to better understand the sensitization process while enabling exploration of therapeutical approaches for food allergy prevention and treatment.
Footnote |
† Electronic supplementary information (ESI) available: Details. See DOI: https://doi.org/10.1039/d4fo01980f |
This journal is © The Royal Society of Chemistry 2024 |